PCT/EP2010/062638
Sanofi-Aventis Deutschland GmbH
48337PWO

Claims

1. Use of desPro^{36}Exendin-4(1-39)-Lys$_6$-NH$_2$ or/and a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for reducing postprandial plasma glucose concentration in a diabetes type 2 patients, wherein the diabetes type 2 patient to be treated has a 2 hours postprandial plasma glucose concentration of at least 14 mmol/L.

2. The use according to claim 1, wherein the subject to be treated is obese.

3. The use according to claim 1 or 2, wherein the subject to be treated has a body mass index of at least 30 kg/m^2.

4. The use according to any of the preceding claims, wherein the subject to be treated is an adult subject.

5. The use according to any of the claims 1 to 4, wherein the subject to be treated does not receive an antidiabetic treatment.

6. The use of any of the preceding claims, wherein in the subject to be treated, diabetes mellitus type 2 has been diagnosed at least 1 year or at least 2 years before onset of therapy.

7. The use of any of the preceding claims, wherein the subject to be treated has a HbA_{1c} value of about 7 to about 10%.

8. The use of any of the preceding claims, wherein the subject to be treated has a fasting plasma glucose concentration of at least 8 mmol/L.

9. The use of any of the preceding claims, wherein the subject to be treated has a glucose excursion of at least 2 mmol/L, at least 3 mmol/L, at least 4 mmol/L or at least 5 mmol/L, wherein the glucose excursion is the difference of the 2 hours postprandial plasma glucose concentration and plasma glucose concentration 30 minutes prior to a meal test.

10. The use of any of the preceding claims, wherein the desPro^{36}Exendin-4(1-39)-Lys$_6$-NH$_2$ or/and the pharmaceutically acceptable salt thereof is administered parenterally.

11. The use according to any of the preceding claims, wherein the medicament is prepared for administration of desPro^{36}Exendin-4(1-39)-Lys$_6$-NH$_2$ or/and the pharmaceutically acceptable salt thereof in a daily dose selected from the range of 10 µg to 20 µg.

12. The use according to any of the preceding claims, wherein the medicament is prepared for once daily administration.

13. A pharmaceutical composition comprising desPro^{36}Exendin-4(1-39)-Lys$_6$-NH$_2$ or/and a pharmaceutically acceptable salt thereof, and optionally comprising pharmaceutically acceptable carriers, adjuvants, or/and auxiliary substances, for use in reducing postprandial plasma glucose concentration in a diabetes type 2 patient, wherein the diabetes type 2 patient to be treated has a 2 hours postprandial plasma glucose concentration of at least 14 mmol/L.

14. The composition of claim 13 for use in the treatment of a subject as defined in any one of the claims 2 to 9.

15. A method for reducing postprandial plasma glucose concentration in a diabetes type 2 patient, wherein the diabetes type 2 patient to be treated has a 2 hours postprandial plasma glucose concentration of at least 14

mmol/L, said method comprising administering desPro^{36}Exendin-4(1-39)-Lys_6-NH_2 or/and a pharmaceutically acceptable salt thereof to a subject in need thereof.

16. The method of claim 15, wherein the subject is the subject defined in any one of the claims 2 to 9.

02.10.12 DI

Claims

1. Use of desPro^{36}Exendin-4(1-39)-Lys$_6$-NH$_2$ or/and a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for reducing postprandial plasma glucose concentration in a diabetes type 2 patients, wherein the diabetes type 2 patient to be treated has a 2 hours postprandial plasma glucose concentration of at least 14 mmol/L; wherein the subject to be treated does not receive an antidiabetic treatment.

2. The use according to claim 1, wherein the subject to be treated is obese.

3. The use according to claim 1 or 2, wherein the subject to be treated has a body mass index of at least 30 kg/m^2.

4. The use according to any of the preceding claims, wherein the subject to be treated is an adult subject.

5. The use of any of the preceding claims, wherein in the subject to be treated, diabetes mellitus type 2 has been diagnosed at least 1 year or at least 2 years before onset of therapy.

6. The use of any of the preceding claims, wherein the subject to be treated has a HbA_{1c} value of about 7 to about 10%.

7. The use of any of the preceding claims, wherein the subject to be treated has a fasting plasma glucose concentration of at least 8 mmol/L.

8. The use of any of the preceding claims, wherein the subject to be treated has a glucose excursion of at least 2 mmol/L, at least 3 mmol/L, at least 4 mmol/L or at least 5 mmol/L, wherein the glucose excursion is the difference of the 2 hours postprandial plasma glucose concentration and plasma glucose concentration 30 minutes prior to a meal test.

9. The use of any of the preceding claims, wherein the desPro^{36}Exendin-4(1-39)-Lys$_6$-NH$_2$ or/and the pharmaceutically acceptable salt thereof is administered parenterally.

10. The use according to any of the preceding claims, wherein the medicament is prepared for administration of desPro^{36}Exendin-4(1-39)-Lys$_6$-NH$_2$ or/and the pharmaceutically acceptable salt thereof in a daily dose selected from the range of 10 µg to 20 µg.

11. The use according to any of the preceding claims, wherein the medicament is prepared for once daily administration.

12. A pharmaceutical composition comprising desPro^{36}Exendin-4(1-39)-Lys6-NH$_2$ or/and a pharmaceutically acceptable salt thereof, and optionally comprising pharmaceutically acceptable carriers, adjuvants, or/and auxiliary substances, for use in reducing postprandial plasma glucose concentration in a diabetes type 2 patient, wherein the diabetes type 2 patient to be treated has a 2 hours postprandial plasma glucose concentration of at least 14 mmol/L; wherein the subject to be treated does not receive an antidiabetic treatment.

13. The composition of claim 12 for use in the treatment of a subject as defined in any one of the claims 2 to 8.

14. Use of the compound desPro^{36}Exendin-4(1-39)-Lys$_6$-NH$_2$, or/and a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for reducing postprandial plasma glucose concentration in a diabetes type 2 patient, wherein the diabetes type 2 patient to be treated has a 2 hours postprandial plasma glucose concentration of at least 14

mmol/L; wherein the subject to be treated does not receive an antidiabetic treatment.

15. The use of claim 14, wherein the subject is the subject defined in any one of the claims 2 to 8.